Status:
ENROLLING_BY_INVITATION
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
Lead Sponsor:
Novo Nordisk A/S
Collaborating Sponsors:
AstraZeneca
Eli Lilly and Company
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
This study is conducted in the United States of America (USA). The aim of the study is to monitor the number of annual new adult cases of medullary thyroid carcinoma (MTC) and to establish a registry ...
Detailed Description
This active surveillance program will monitor for any signal indicating a possible association between treatment with long-acting GLP-1 RAs and the development of MTC in the United States population. ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- A record of medullary thyroid carcinoma (MTC) identified from state/regional population-based cancer registries
- At least 18 years or older.
- There are no other inclusion or exclusion criteria.
Exclusion
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2039
Estimated Enrollment :
6750 Patients enrolled
Trial Details
Trial ID
NCT01511393
Start Date
January 1 2012
End Date
December 1 2039
Last Update
June 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
United BioSource, LLC
Morgantown, West Virginia, United States, 26505-8065